Skip to main content

Chemotherapy-Induced Nausea and Vomiting (CINV)

10
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
6
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
4 programs
1
3
Comparator: fosaprepitant dimegluminePhase 3
Fosaprepitant dimegluminePhase 3
aprepitantPhase 3
Fosaprepitant 150 mgPhase 1
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
4 programs
1
3
Comparator: fosaprepitant dimegluminePhase 31 trial
Fosaprepitant dimegluminePhase 31 trial
aprepitantPhase 31 trial
Fosaprepitant 150 mgPhase 11 trial
Active Trials
NCT01111851Completed16Est. Oct 2010
NCT00619359Completed2,322Est. Jun 2009
NCT01594749Completed1,015Est. Nov 2014
+1 more trials
Helsinn
HelsinnIreland - Dublin
1 program
1
NetupitantPhase 21 trial
Active Trials
NCT03204279Completed67Est. Sep 2019
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
apripitant and palonosetron injectable emulsionPhase 11 trial
Active Trials
NCT07817004Not Yet Recruiting42Est. Dec 2026
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Fosaprepitant dimegluminePHASE_3
Heron Therapeutics
1 program
SUSTOLPHASE_41 trial
Active Trials
NCT05434663Active Not Recruiting300Est. Oct 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Heron TherapeuticsSUSTOL
Sharp TherapeuticsFosaprepitant dimeglumine
Sharp Therapeuticsaprepitant
Sharp TherapeuticsComparator: fosaprepitant dimeglumine
HelsinnNetupitant
Qilu Pharmaceuticalapripitant and palonosetron injectable emulsion
Sharp TherapeuticsFosaprepitant 150 mg

Clinical Trials (7)

Total enrollment: 4,183 patients across 7 trials

NCT05434663Heron TherapeuticsSUSTOL

Safety Study of Repeat Doses of SUSTOL in Adults

Start: Jul 2022Est. completion: Oct 2025300 patients
Phase 4Active Not Recruiting
NCT01594749Sharp TherapeuticsFosaprepitant dimeglumine

Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)

Start: Sep 2012Est. completion: Nov 20141,015 patients
Phase 3Completed
NCT00952341Sharp Therapeuticsaprepitant

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Start: Aug 2009Est. completion: May 2010421 patients
Phase 3Completed
NCT00619359Sharp TherapeuticsComparator: fosaprepitant dimeglumine

Evaluation of Fosaprepitant (MK0517) in Single Dose Schedule (0517-017)

Start: Feb 2008Est. completion: Jun 20092,322 patients
Phase 3Completed
NCT03204279HelsinnNetupitant

PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting

Start: Aug 2017Est. completion: Sep 201967 patients
Phase 2Completed
NCT07817004Qilu Pharmaceuticalapripitant and palonosetron injectable emulsion

QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration

Start: Sep 2026Est. completion: Dec 202642 patients
Phase 1Not Yet Recruiting
NCT01111851Sharp TherapeuticsFosaprepitant 150 mg

Aprepitant and Fosaprepitant Time-on-Target PET (Positron Emission Tomography) Study (0869-183)

Start: Apr 2010Est. completion: Oct 201016 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

6 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.